Erytech Pharma S.A. (ERYP): Price and Financial Metrics


Erytech Pharma S.A. (ERYP)

Today's Latest Price: $9.52 USD

1.54 (19.30%)

Updated Nov 27 12:43pm

Add ERYP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ERYP Stock Summary

  • With a one year PEG ratio of 0.52, Erytech Pharma SA is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 6.33% of US stocks.
  • With a price/sales ratio of 29.11, Erytech Pharma SA has a higher such ratio than 93.21% of stocks in our set.
  • With a year-over-year growth in debt of 350.85%, Erytech Pharma SA's debt growth rate surpasses 95.21% of about US stocks.
  • Stocks that are quantitatively similar to ERYP, based on their financial statements, market capitalization, and price volatility, are ACIU, VCNX, NVEC, VNE, and CBIO.
  • ERYP's SEC filings can be seen here. And to visit Erytech Pharma SA's official web site, go to www.erytech.com.

ERYP Stock Price Chart Interactive Chart >

Price chart for ERYP

ERYP Price/Volume Stats

Current price $9.52 52-week high $13.95
Prev. close $7.98 52-week low $3.50
Day low $8.95 Volume 1,800
Day high $9.70 Avg. volume 4,038
50-day MA $6.74 Dividend yield N/A
200-day MA $7.01 Market Cap 180.84M

Erytech Pharma S.A. (ERYP) Company Bio


ERYTECH Pharma Société Anonyme, a clinical-stage biopharmaceutical company, develops therapies for rare forms of cancer and orphan diseases in France and internationally. The company is developing a pipeline of product candidates targeting markets with unmet medical need using its proprietary ERYCAPS platform, a technology to encapsulate therapeutic drug substances inside red blood cells. It primarily focuses on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company was founded in 2004 and is based in Lyon, France.


ERYP Latest News Stream


Event/Time News Detail
Loading, please wait...

ERYP Latest Social Stream


Loading social stream, please wait...

View Full ERYP Social Stream

Latest ERYP News From Around the Web

Below are the latest news stories about Erytech Pharma SA that investors may wish to consider to help them evaluate ERYP as an investment opportunity.

Erytech inks $30M stock sales deal with Cowen

ERYTECH Pharma (ERYP) inks at-the-market sales agreement with Cowen for the sale of ordinary shares in the form of American Depositary Shares (ADSs) for gross sales proceeds of up to $30M.The ATM program will be effective until September 21, 2023, unless terminated prior to such date. Net proceeds will be...

Seeking Alpha | September 22, 2020

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q2 2020 Results - Earnings Call Transcript

ERYTECH Pharma S.A. (ERYP) Q2 2020 Earnings Conference Call September 22, 2020 8:30 A.M. ET Company Participants Gil Beyen - Chief Executive Officer Eric Soyer - Chief Financial Officer and Chief Operating Officer Iman El-Hariry - Chief Medical Officer Conference Call Participants Fred Gomez - Pharmium Securities Justin Walsh -...

SA Transcripts on Seeking Alpha | September 22, 2020

ERYTECH establishes a financing facility with the implementation of an at-the-market program on Nasdaq with Cowen

LYON, France, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), a clinical-stage biopharmaceutical company…

GlobeNewswire | September 21, 2020

ERYTECH to Host on September 22, 2020 Second Quarter 2020 Conference Call and Business Update

LYON, France, Sept. 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company…

GlobeNewswire | September 16, 2020

The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Allovir Inc (NASDAQ: ALVR ) Erytech Pharma SA (NASDAQ: ERYP ) Eyenovia Inc (NASDAQ: EYEN ) (announced an exclusive collaboration and licensing agreement for MicroLine and MicroPine in Greater China and South Korea) Evoke Pharma Inc (NASDAQ: EVOK ) Fortress Biotech (NASDAQ: FBIO )(reacted to its second-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) Inari Medical Inc (NASDAQ: NARI ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Kura Oncology Inc (NASDAQ: KURA ) OncoSec Medical Inc (NASDAQ: ONCS ) Orthopediatrics Corp (NASDAQ: KIDS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Down In The Dumps (Biotech Stocks Hittin...

Benzinga | August 12, 2020

Read More 'ERYP' Stories Here

ERYP Price Returns

1-mo N/A
3-mo 36.98%
6-mo 5.68%
1-year N/A
3-year -65.69%
5-year N/A
YTD 29.08%
2019 8.94%
2018 -69.26%
2017 N/A
2016 N/A
2015 N/A

Continue Researching ERYP

Want to see what other sources are saying about Erytech Pharma SA's financials and stock price? Try the links below:

Erytech Pharma SA (ERYP) Stock Price | Nasdaq
Erytech Pharma SA (ERYP) Stock Quote, History and News - Yahoo Finance
Erytech Pharma SA (ERYP) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8671 seconds.